LLY stock slips as Street defends Alzheimer’s setback (NYSE:LLY)

Alzheimers Concept Horizontal


Eli Lilly (NYSE:LLY) continued to say no within the morning hours Friday even as a number of analysts defended the corporate after the FDA refused accelerated approval for its Alzheimer’s remedy donanemab.

Cantor Fitzgerald’s Louise Chen leads the pack, reaffirming the OverweightLLY

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!